HEALTHJun 6 · 20:54 UTCSTAT NEWSElizabeth Cooney

STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending

The American Diabetes Association annual conference highlights new diabetes treatments, including triple hormone receptors and a monthly obesity drug. The article summarizes key developments from the event.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

American Diabetes Associationorganizationtriple hormone receptorstopicmonthly obesity drugtopicSTATorganizationSTAT+organization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 18 · 00:00 UTC
Publisher Correction: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
HEALTHMay 14 · 11:00 UTC
Experimental obesity drug outperforms traditional weight-loss treatments in early research
HEALTHMay 26 · 12:43 UTC
Welcome to the Injection Age
HEALTHJun 6 · 18:32 UTC
STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
HEALTHMay 21 · 13:28 UTC
STAT+: Pharmalittle: We’re reading about a Lilly obesity drug trial, statistics for an Alzheimer’s drug, and more
HEALTHMay 28 · 13:26 UTC
STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more